View : 15 Download: 0

Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study

Title
Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study
Authors
Lee, Sung-EunChoi, Soo YoungSong, Hye-YoungKim, Soo-HyunChoi, Mi-YeonPark, Joon SeongKim, Hyeoung-JoonKim, Sung-HyunZang, Dae YoungOh, SukjoongKim, HawkDo, Young RokKwak, Jae-YongKim, Jeong-AKim, Dae-YoungMun, Yeung-ChulLee, Won SikChang, Myung HeePark, JinnyKwon, Ji HyunKim, Dong-Wook
Ewha Authors
문영철
SCOPUS Author ID
문영철scopus
Issue Date
2016
Journal Title
HAEMATOLOGICA
ISSN
0390-6078JCR Link
Citation
vol. 101, no. 6, pp. 717 - 723
Publisher
FERRATA STORTI FOUNDATION
Indexed
SCI; SCIE; SCOPUS WOS scopus
Abstract
The aim of the Korean Imatinib Discontinuation Study was to identify predictors for safe and successful imatinib discontinuation. A total of 90 patients with a follow-up of >= 12 months were analyzed. After a median follow-up of 26.6 months after imatinib discontinuation, 37 patients lost the major molecular response. The probability of sustained major molecular response at 12 months and 24 months was 62.2% and 58.5%, respectively. All 37 patients who lost major molecular response were retreated with imatinib therapy for a median of 16.9 months, and all achieved major molecular response again at a median of 3.9 months after resuming imatinib therapy. We observed newly developed or worsened musculoskeletal pain and pruritus in 27 (30%) patients after imatinib discontinuation. Imatinib withdrawal syndrome was associated with a higher probability of sustained major molecular response (P=0.003) and showed a trend for a longer time to major molecular response loss (P=0.098). Positivity (defined as >= 17 positive chambers) of digital polymerase chain reaction at screening and longer imatinib duration before imatinib discontinuation were associated with a higher probability of sustained major molecular response. Our data demonstrated that the occurrence of imatinib withdrawal syndrome after imatinib discontinuation and longer duration of imatinib were associated with a lower rate of molecular relapse. In addition, minimal residual leukemia measured by digital polymerase chain reaction had a trend for a higher molecular relapse.
DOI
10.3324/haematol.2015.139899
Appears in Collections:
의학전문대학원 > 의학과 > Journal papers
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE